Pioneering CRISPR Breakthroughs Unveiled at Allogeneic Cell Summit 2025
June 10, 2025
uBriGene is proud to announce our participation in the 7th Annual Allogeneic Cell Therapies Summit, taking place at Revere Hotel Boston Common from June 10–12, 2025.
As a global CDMO with deep expertise in advanced therapy development, we’re excited to contribute to one of the field’s most influential gatherings of allogeneic cell therapy leaders, innovators, and translational scientists.
Our team will present a scientific poster at the summit on Wednesday, June 11, from 2:30 to 3:30 PM, titled: Novel sgRNA IVT Platform for Allogeneic Cell Therapies
CRISPR gene editing has become foundational in clinical-stage cell and gene therapies, with guide RNA (gRNA) playing a critical role in precise genome modifications. Traditionally, sgRNA is chemically synthesized, a method that involves organic solvents and poses limitations in scalability and cost.
uBriGene has developed an innovative in vitro transcription (IVT) platform for sgRNA production, offering a more scalable and cost-efficient alternative to chemical synthesis. This technology has demonstrated higher gene editing efficiency, especially when paired with uBriGene’s GMP-grade Cas9 proteins and closed-end linear DNA templates.
Our poster presentation reflects our continued investment in client-centric, next-generation CRISPR solutions. With a focus on quality, innovation, and translational readiness, uBriGene is committed to accelerating the path from research to clinical success in allogeneic and genome-engineered therapies.
We look forward to engaging with you at the summit in Boston! Learn more about the event at the 7th Annual Allogeneic Cell Therapies Summit.